President Trump’s renewed tariff threats, including a levy on generic drugs, risk harming Canadian exporters and disrupting a crucial supply chain. Canada supplies about 20% of the generic medications used in the United States, and any new tariffs could raise drug prices for American patients while squeezing Canadian manufacturers.
The tariffs also threaten broader trade relations. Canada is the U.S.’s second-largest trading partner, and tit-for-tat measures could escalate into a full-blown trade war. Past tariffs on steel and aluminum led to Canadian retaliation on U.S. goods, hurting farmers and manufacturers on both sides.
For Canadian businesses, the uncertainty alone is damaging. Companies may delay investments or relocate supply chains to avoid potential costs. The generic drug industry, in particular, operates on thin margins, and even a modest tariff could make cross-border production unviable.
Trump’s focus on protecting U.S. manufacturing overlooks the integrated nature of North American supply chains. Many products cross the border multiple times before reaching consumers. Tariffs impose costs that ultimately hit end users, including American households. A more cooperative approach would better serve both economies.